Covid vaccine makers sidelined ahead of ACIP meeting Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 16 September, 2025

Endpoints News returns to Boston’s State Room to announce the 2025 class of biotechs worth watching. Join the live unveiling and see the industry’s next chapter come into focus. Which biotechs will make the leap? Join us.

news Genmab ends work on ADC from $1.8B acquisition of ProfoundBio CSL commits $117M to help bring VarmX’s blood clotting drug to market Covid-19 vaccine makers sidelined ahead of upcoming ACIP meeting, sources say •  RFK Jr. adds five new ACIP panelists, including more vaccine critics and skeptics Dualitas gets $65M in Series A to develop bispecifics for immunology Former CinCor executives return with new ‘hub-and-spoke’ company, old Sanofi drug Exclusive: Fred Hutch duo's startup launches with $10M to build AI generative genomics models

Sep 23 11:00am ET Data you can trust: Setting the bar for ML/LLM-extracted real-world data sponsored by Flatiron Sep 25 11:00am ET Speed meets precision: Unlocking high-parameter flow cytometry with acoustic focusing sponsored by Thermo Fisher Oct 02 10:30am ET Unlocking patient access: Modernizing clinical trial regulatory frameworks and trial delivery sponsored by Lilly Oct 21 11:00am ET AI in life sciences: Reimagining teams, technology and partnerships for the future sponsored by Zaidyn by ZS

Biopharma is grappling with diverging policies between the US, EU, and Asia — including proposed drug pricing reforms in the US and new EU regulations taking effect this year. The need for strategic clarity has never been more urgent. Join us in London — in person and virtually — where we’re bringing together the industry’s most influential voices to chart a path forward.

endpoints pharma ‘A concerning pattern’: Pharma mulls UK divestments as government action lags in life sciences Bristol Myers to sell 60% stake in China-US joint venture AbbVie loses appeal over Mississippi 340B state law FDA calls out AstraZeneca's flu vaccine TV ad amid regulatory blitz

in case you missed it 1. aTyr Pharma’s stock plummets after Phase 3 flop in inflammatory lung disease 2. Updated: Novartis extends deal spree with $120M for Monte Rosa's immune degraders 3. Lila Sciences says it has raised $235M to go 'all gas, no brake' on its AI-for-science bet •  Exclusive: Lila Sciences is closing in on $300M+ fundraise at $1B+ valuation, to scale up its bet on autonomous science 4. News Briefing